Heron Announces Positive Topline Results from Phase 2b Clinical Studies of HTX-011 in Total Knee Arthroplasty and Breast Augmentation

Go back to Heron Announces Positive Topline Results from Phase 2b Clinical Studies of HTX-011 in Total Knee Arthroplasty and Breast Augmentation
HERON THERAPEUTICS (NASDAQ: HRTX) Delayed: 0.40 -0.01 (2.44%)
Previous Close $0.41    52 Week High $31.32 
Open $0.41    52 Week Low $13.95 
Day High $0.41    P/E N/A 
Day Low $0.40    EPS $-3.29 
Volume 4,557,608